- Home
- CERO vs USEA Comparison
CERO vs USEA Comparison
Compare CERO & USEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- USEA
- Stock Information
- Founded
- CERO 2017
- USEA 2004
- Country
- CERO United States
- USEA Greece
- Employees
- CERO N/A
- USEA N/A
- Industry
- CERO
- USEA Marine Transportation
- Sector
- CERO
- USEA Consumer Discretionary
- Exchange
- CERO Nasdaq
- USEA Nasdaq
- Market Cap
- CERO 9.6M
- USEA 10.5M
- IPO Year
- CERO N/A
- USEA N/A
- Fundamental
- Price
- CERO $8.25
- USEA $1.58
- Analyst Decision
- CERO Strong Buy
- USEA
- Analyst Count
- CERO 2
- USEA 0
- Target Price
- CERO $45.00
- USEA N/A
- AVG Volume (30 Days)
- CERO 40.2K
- USEA 21.3K
- Earning Date
- CERO 08-29-2025
- USEA 08-06-2025
- Dividend Yield
- CERO N/A
- USEA 2.63%
- EPS Growth
- CERO N/A
- USEA N/A
- EPS
- CERO N/A
- USEA N/A
- Revenue
- CERO N/A
- USEA $42,625,000.00
- Revenue This Year
- CERO N/A
- USEA N/A
- Revenue Next Year
- CERO N/A
- USEA $11.62
- P/E Ratio
- CERO N/A
- USEA N/A
- Revenue Growth
- CERO N/A
- USEA N/A
- 52 Week Low
- CERO $6.71
- USEA $1.00
- 52 Week High
- CERO $895.40
- USEA $2.78
- Technical
- Relative Strength Index (RSI)
- CERO 49.24
- USEA 51.76
- Support Level
- CERO $8.07
- USEA $1.50
- Resistance Level
- CERO $8.90
- USEA $1.57
- Average True Range (ATR)
- CERO 0.40
- USEA 0.07
- MACD
- CERO 0.11
- USEA -0.01
- Stochastic Oscillator
- CERO 59.38
- USEA 34.09
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.